Lipid-lowering therapy in patients with type 2 diabetes: The case for early intervention

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 4, 2008, Pages 286-293

  Steinmetz, Armin ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cardiovascular disease; Early intervention; Fenofibre; Statin; Type 2 diabetes; Vascular complications

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; RIMONABANT; SIMVASTATIN; SULFONYLUREA;

ALBUMINURIA; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EARLY INTERVENTION; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; MORBIDITY; MORTALITY; MYOSITIS; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HUMANS; RISK FACTORS; SAFETY;

EID: 44949240663     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.806     Document Type: Review

References (51)

1. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.
2. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
3. Vinik AI, Vinik E. Prevention of the complications of diabetes. Am J Manag Care 2003; 9: S63-S80.
4. Skyler JS. Microvascular complications. Retinopathy and nephropathy. Endocrinol Metab Clin North Am 2001; 30: 833-856.
5. Jawa A, Kcomt J, Fonseca VA. Diabetic nephropathy and retinopathy. Med Clin North Am 2004; 88: 1001-1036, DOI: 10.1016/ j.mcna.2004.04.012.
6. Center for Disease Control. Lower extremity disease among persons aged ≥40 years with and without diabetes-United States, 1999-2002. MMWR Wkly 2005; 54:1158-1160, Available from http://www.cdc.gov/ mmwr/preview/mmwrhtml/mm5445a4.htm [Accessed 29 June 2006].
7. Vinik AI, Park TS, Stansberry KB, et al. Diabetic neuropathies. Diabetologia 2000; 43: 957-973, DOI: 10.1007/S001250051477.
8. Kendall DM, Bergenstal RM. Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care 2001; 7: S327-S343.
9. Wingard DL, Barrett-Connor EL, Scheidt-Nave C, et al. Prevalence of cardiovascular and renal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993; 16: 1022-1025.
10. Bate KL, Jerums G. Practice essentials. 3: Preventing complications of diabetes. Med J Aust 2003; 179: 498-503.
11. Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD. ABC of arterial and venous disease: vascular complications of diabetes. BMJ 2000; 320: 1062-1066, DOI: 10.1 136/bmj.320.7241.1062.
12. Cusick M, Meleth AD, Agros E, et al. Association of mortality and diabetes complications in patients with type 1 and type 2 diabetes. Early Treatment Diabetic Retinopathy Study report no. 27. Diabetes Care 2005; 28: 617-625.
13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853, DOI: 10.1016/ s0140-6736(98)07019-6.
14. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865, DOI: 10.1016/S0140-6736(98)07037-8.
15. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316:823-828.
16. Lamarche B, Tchernhof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
17. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998; 19(Suppl. A): A2-A11.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
19. International Atherosclerosis Society. Harmonizzed Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease. Available from http://www.athero.org [Accessed 20 June 2006].
20. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006; 29: S4-S42.
21. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278, DOI: 10.1016/S0140-6736(05)67394-1.
22. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006; 332: 1115-1124, DOI: 10.1136/bmj.38793.468.449.AE.
23. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016, DOI: 10.1016/S0140-6736(03)13636-7.
24. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696, DOI: 10.1016/S0140-6736(04)16895-5.
25. Knopp RH, D'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular endpoints in subjects with type 2 diabetes. The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485, DOI: 10.2337/ dc05-2415.
26. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
27. Sever PSS, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158, DOI: 10.1016/S0140-6736(03)12948-0.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
29. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006; 81: 1579-1588.
30. Chapman MJ. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003; 171: 1-13, DOI: 10.1016/S0021-9150(03)00156-4.
31. Birjmohun RS, Hutten BA, Kastelein JJP, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-197, DOI: 10.1016/j.jacc.2004.10.031.
32. Feher MD, Caslake M, Foxton J, et al. Atherogenic lipoprotein phenotype in type 2 diabetes: reversal with micronised fenofibrate. Diabetes Metab Res Rev 1999; 15: 395-399, DOI: 10.1002(SICI)1520-7560(199911/12)15:6<390::AID-DMRR67>3.0.CO;2-W.
33. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Study (DAIS). Circulation 2003; 107: 1733-1737, DOI: 10.1161/01.CIR.0000057982.50167.6E.
34. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
35. The Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes; the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910, DOI: 10.1016/ s0140-6736(00)04209-4.
36. The FIELD study investigators. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861, DOI: 10.1016/S0140-6736(05)67667-2.
37. Keech A, Simes J, Barter P, et al. Correction to the FIELD study report. Lancet 2006; 368: 1415-1420.
38. Di Matzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
39. Poirier B, Bidouard JP, Cardrouvele C, et al. The anti-obesity effect of rimonabant is associated with improved serum lipid profile. Diabetes Obes Metab 2005; 7: 65-72.
40. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. RIO-Diabetes Study Group. Lancet 2006; 368: 1660-1672, for the DOI: 10.1016/s0140-673606)69571-8.
41. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317: 691-694.
42. Stratton IM, Adler AI, Neil AW, et al. Association of glycaemia with macrovascular and microvasculor complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412, DOI: 10.1136/bmj.321.7258.405.
43. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
44. Misra A, Kumar S, Kishore-Vikram N, Komar A. The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs 2003; 3: 325-338.
45. Leiter LA. The prevention of diabetic microvascular complications of diabetes: Is there a!role for lipid lowering? Diabetes Res Clin Pract 2005; 68(Suppl. 2): S3-S14, DOI: 10.1016/ j.diabetes.2005.03.015.
46. Koh KK, Han SW, Quon MJ, et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005; 28: 1419-1424.
47. Ansquer JC, Foucher C, Rattier S, et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-493.
48. Keech A, on behalf of the FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events among 9795 people with type 2 diabetes mellitus: the FIELD study, a randomised, controlled trial. Atheroscler Suppl 2006; 7: 342, [Abstract We-S15].
49. Davidson MH. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf 2006; 5: 145-156, DOI: 10.1517/14740338.5.1.145.
50. Jacobson TA, Zimmerman FH. Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 2006; 8: 35-41.
51. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Available from www.accordtrial.org, accessed 13 February 2006.